Skip to main navigation Skip to search Skip to main content

Pharmaceutical strategies for reducing ldl-c and risk of cardiovascular disease

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Original languageEnglish
Title of host publicationAdvances in Surgical and Medical Specialties
PublisherTaylor and Francis
Pages305-316
Number of pages12
ISBN (Electronic)9781000602746
ISBN (Print)9789814877459
Publication statusPublished - 23 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alirocumab
  • Atherogenic dyslipidaemia
  • Atherosclerosis
  • Atorvastatin
  • Bococizumab
  • Canakinumab
  • Cardiovascular disease
  • Combination therapy
  • Evolocumab
  • Ezetimibe
  • Ezetimibe-atorvastatin therapy
  • Familial hypercholesterolaemia (FH)
  • Fenofibrate
  • Hyper-cholesterolaemia
  • Inclisiran
  • Ischaemic stroke
  • Low-density lipoprotein cholesterol (LDL-C)
  • Low-dose methotrexate
  • Myocardial infarction
  • PCSK9 inhibition therapy
  • Polypill
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
  • Ribonucleic acid (RNA)
  • Rosuvastatin
  • Simvastatin
  • Small interfering ribonucleic acid
  • Statin intolerance
  • Statin potency
  • Statin-ezetimibe combination therapy
  • Statin-fibrate combinations
  • Statins
  • Unstable angina

Cite this